Comparison of a new Light Diagnostics™ and the CMV Brite™ to an in-house developed human cytomegalovirus antigenemia assay

Elena Percivalle, Emilia Genini, Antonella Chiesa, Giuseppe Gerna

Research output: Contribution to journalArticle

Abstract

Background: Antigenemia, i.e. detection and quantification of human cytomegalovirus (HCMV) peripheral blood pp65-positive leukocytes, is still one of the two major assays available for diagnosis and monitoring of HCMV infections. Objectives: To evaluate the performance of a new commercial assay under development (Light Diagnostics™). Study design: To compare the performance of the new assay with a commercial assay (CMV Brite™) already available on 300 blood samples from immunocompromised patients using as a reference the original in-house developed assay. Results: Although 30 blood samples gave discrepant results among the 3 antigenemia assays, the Light Diagnostics™ detected an overall number of antigenemia-positive blood samples (sensitivity 84%) identical to that detected by CMV Brite™ (sensitivity 88%) and in-house assay (91/300, 30.3%). Problems of non-specific cytoplasmic staining were encountered with the CMV Brite™ assay in 219/300 (73%) blood samples. Conclusions: The Light Diagnostics™ assay provides results comparable to those of the reference assay both in terms of specificity and sensitivity (number of pp65-positive leukocytes).

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalJournal of Clinical Virology
Volume43
Issue number1
DOIs
Publication statusPublished - Sep 2008

Keywords

  • DNAemia
  • Human cytomegalovirus
  • Immunocompromised patients
  • PCR
  • pp65-antigenemia

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparison of a new Light Diagnostics™ and the CMV Brite™ to an in-house developed human cytomegalovirus antigenemia assay'. Together they form a unique fingerprint.

  • Cite this